← Leaderboards
John Phillip Konsin
Prapela, Inc.
$2,694,472
Attributed
$6,320,248
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,320,248 · 3
By mechanism
U44$3,460,586 · 1
R44$2,637,437 · 1
R43$222,225 · 1
Top collaborators
- Rachana Singh6 shared
- Namasivayam Ambalavanan3 shared
Others in their field
Other Emerging Leaders on “Infant”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$29,616,650
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,941,048
- Robert Wilson Frenck · Cincinnati Childrens Hosp Med Ctr$15,645,835
- Sara Bonamo Demauro · Children'S Hosp Of Philadelphia$11,606,693
- Rajni Samavedam · Booz Allen Hamilton$9,935,296
Research focus
InfantCaringCost EffectiveNewborn InfantHospitalsTechnologyDevicesMedical DeviceVibrotactile StimulationSmall Business Innovation Research GrantHeart RateInfant CarePediatricsBreathingClinical ResearchReportingCommercializationMarketingSafetyBiomaterial CompatibilityPrimary OutcomePrototypeElectromagneticsFuture
Grant awards (7)
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$1,475,909
U44 · FY2025 · DA · contact PI
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$1,484,463
U44 · FY2024 · DA · contact PI
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$500,214
U44 · FY2023 · DA · contact PI
Prapela⢠SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.$137,437
R44 · FY2023 · DA · contact PI
Prapela⢠SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.$1,169,404
R44 · FY2022 · DA · contact PI
Prapela⢠SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.$1,330,596
R44 · FY2021 · DA · contact PI
Prapela⢠SVS: A cost-effective stochastic vibrotactile stimulation device to improve the clinical course of infants with neonatal abstinence syndrome.$222,225
R43 · FY2019 · DA · contact PI